Al-Qassabi A, Fereshtehnejad S, Postuma R
Curr Treat Options Neurol. 2017; 19(6):22.
PMID: 28466429
DOI: 10.1007/s11940-017-0458-1.
McGrane I, Leung J, St Louis E, Boeve B
Sleep Med. 2014; 16(1):19-26.
PMID: 25454845
PMC: 4306603.
DOI: 10.1016/j.sleep.2014.09.011.
Mignot E
Immunol Res. 2014; 58(2-3):315-39.
PMID: 24825774
PMC: 4028550.
DOI: 10.1007/s12026-014-8513-4.
Brown R, Basheer R, McKenna J, Strecker R, McCarley R
Physiol Rev. 2012; 92(3):1087-187.
PMID: 22811426
PMC: 3621793.
DOI: 10.1152/physrev.00032.2011.
Boucetta S, Jones B
J Neurosci. 2009; 29(14):4664-74.
PMID: 19357291
PMC: 6665745.
DOI: 10.1523/JNEUROSCI.5502-08.2009.
Why we sleep: the temporal organization of recovery.
Mignot E
PLoS Biol. 2008; 6(4):e106.
PMID: 18447584
PMC: 2689703.
DOI: 10.1371/journal.pbio.0060106.
The stuff dreams are made of: anatomical substrates of REM sleep.
Siegel J
Nat Neurosci. 2006; 9(6):721-2.
PMID: 16732200
PMC: 8779714.
DOI: 10.1038/nn0606-721.
c-Fos expression in GABAergic, serotonergic, and other neurons of the pontomedullary reticular formation and raphe after paradoxical sleep deprivation and recovery.
Maloney K, Mainville L, Jones B
J Neurosci. 2000; 20(12):4669-79.
PMID: 10844036
PMC: 6772475.
Differential c-Fos expression in cholinergic, monoaminergic, and GABAergic cell groups of the pontomesencephalic tegmentum after paradoxical sleep deprivation and recovery.
Maloney K, Mainville L, Jones B
J Neurosci. 1999; 19(8):3057-72.
PMID: 10191323
PMC: 6782283.
Canine cataplexy is preferentially controlled by adrenergic mechanisms: evidence using monoamine selective uptake inhibitors and release enhancers.
Mignot E, Renaud A, Nishino S, Arrigoni J, Guilleminault C, Dement W
Psychopharmacology (Berl). 1993; 113(1):76-82.
PMID: 7862832
DOI: 10.1007/BF02244337.
A modern neurobiological concept of vigilance.
Koella W
Experientia. 1982; 38(12):1426-37.
PMID: 7151957
DOI: 10.1007/BF01955754.
REM sleep suppression induced by selective monoamine oxidase inhibitors.
Cohen R, Pickar D, Garnett D, Lipper S, Gillin J, Murphy D
Psychopharmacology (Berl). 1982; 78(2):137-40.
PMID: 6817370
DOI: 10.1007/BF00432251.
Imipramine and REM sleep: cholinergic mediation in animals.
Hill S, Reyes R, Kupfer D
Psychopharmacology (Berl). 1980; 69(1):5-9.
PMID: 6771826
DOI: 10.1007/BF00426514.
The organization and regulation of sleep. A review of the experimental evidence and a novel integrated model of the organizing and regulating apparatus.
Koella W
Experientia. 1984; 40(4):309-38.
PMID: 6370714
DOI: 10.1007/BF01952538.
A biphasic action of central cholinergic stimulation on behavioral arousal in the rat.
Fibiger H, Lynch G, Cooper H
Psychopharmacologia. 1971; 20(4):366-82.
PMID: 5561658
DOI: 10.1007/BF00403568.
Effects of reserpine on sleep and brain biogenic amine levels in the cat.
Stern W, Morgane P
Psychopharmacologia. 1973; 28(3):275-86.
PMID: 4347933
DOI: 10.1007/BF00429308.
Effect of the antidepressant Org 3770 on human sleep.
Ruigt G, Kemp B, Groenhout C, Kamphuisen H
Eur J Clin Pharmacol. 1990; 38(6):551-4.
PMID: 2373128
DOI: 10.1007/BF00278580.
Pontine regulation of REM sleep components in cats: integrity of the pedunculopontine tegmentum (PPT) is important for phasic events but unnecessary for atonia during REM sleep.
Shouse M, Siegel J
Brain Res. 1992; 571(1):50-63.
PMID: 1611494
PMC: 9110272.
DOI: 10.1016/0006-8993(92)90508-7.
Physostigmine alters onset but not duration of REM sleep in man.
Gillin J, Sitaram N, Mendelson W, Wyatt R
Psychopharmacology (Berl). 1978; 58(1):111-4.
PMID: 209490
DOI: 10.1007/BF00426799.
